ABCG2 and breast carcinoma: Ribociclib, a CDK4/6 inhibitor approved for the treatment of locally advanced/ metastatic breast cancer, revealed ABCB1 and ABCG2-mediated daunorubicin and mitoxantrone efflux inhibition in AML cell lines and in CD4+/Flt3-WT leukemia cells [117].